Bachground. In spite of decrease in burden of stomach cancer in the developed world, the incidence of this disease is still high in the developing countries including Iran. Due to the slow progression of the cancer within stomach, the cancer is usually diagnosed in advanced stage leading to a high mortality rate. The stomach cancer is the second cause of death due to cancer after lung cancer. In this study, we studied the survival rate of stomach cancer among patients hospitalized in Baghiatollah hospital in Tehran, Iran between 2000 and 2005. Patients and Methods. In overall, we studied the survival rate of 209 patients hospitalized for stomach cancer in Baghiatollah hospital. We used patient files and abstracted demographic data as well as information about stomach tumor, i.e. histopathology, stage of the disease. Crude survival rates were studied by of stomach cancer using Kaplan-Meier and Life Table methods. Cox regression model estimated the effect of demographic information and tumor characteristics on death due to stomach cancer. Results. we found a poor prognosis for our stomach cancer patients. More than 20 percent of patients died of stomach cancer in the first three months and only half of patients were still alive after nine months of follow-up. One, three, and five years survival were 44, 19, and 11 percents, respectively. Stage of tumor was the most important prognostic factor in this study, although patients diagnosed with a stomach cancer staged IB, II, IIIA, and IIIB had almost similar prognosis. Study of 13 patients with stomach lymphoma showed a better survival rate compared to adenocarcinoma in overall. Discussion. stomach cancer patients had a considerably poor prognosis in Iran. Further studies are needed to improve the diagnostic and therapeutic approached to improve the prognosis of these patients.
khedmat H., , Panahian M., , Amini M., , Izadi M., , naseri M. H., , & ghayomi M. H., (2022). survivsl of stomach adenocarcinoma. Journal of Military Medicine, 9(3), 167-177.
MLA
khedmat H.; Panahian M.; Amini M.; Izadi M.; naseri M. H.; ghayomi M. H.. "survivsl of stomach adenocarcinoma". Journal of Military Medicine, 9, 3, 2022, 167-177.
HARVARD
khedmat H., , Panahian M., , Amini M., , Izadi M., , naseri M. H., , ghayomi M. H., (2022). 'survivsl of stomach adenocarcinoma', Journal of Military Medicine, 9(3), pp. 167-177.
VANCOUVER
khedmat H., , Panahian M., , Amini M., , Izadi M., , naseri M. H., , ghayomi M. H., survivsl of stomach adenocarcinoma. Journal of Military Medicine, 2022; 9(3): 167-177.
)